@pubmed.ncbi.nlm.nih.gov.rss-feed.feed.id.1bkd3nt7c-bb2ox2p4gq17anukdwtgc2lcfjxpodg3qewx1czi.utm.content.1bkd3nt7c-bb2ox2p4gq17anukdwtgc2lcfjxpodg3qewx1czi.utm.medium.rss.ff.20260423180744.utm.source.rss-parrot-bot.v.2.19.0.post6.133c1fe@rss-parrot.net
I'm an automated parrot! I relay a website's RSS feed to the Fediverse. Every time a new post appears in the feed, I toot about it. Follow me to get all new posts in your Mastodon timeline! Brought to you by the RSS Parrot.
---
Multiple [TIAB] AND sclerosis [TIAB] AND therapy [TIAB] AND trial: Latest results from PubMed
Feed URL: pubmed.ncbi.nlm.nih.gov/rss/search/1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI/
Posts: 8
Followers: 1
Assessing the value of oligoclonal band count in multiple sclerosis: insights from a large cohort analysis
Published: May 4, 2026 10:00
Cerebrospinal fluid (CSF) specific oligoclonal bands (OCB) are a key diagnostic marker in multiple sclerosis (MS). Recent studies suggest that OCB reduction may reflect treatment efficacy and propose it as a potential endpoint in trials with chimeric…
No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathy
Published: May 1, 2026 10:00
CONCLUSIONS: These findings do not suggest a contributing role for IFN-β NAbs in natalizumab-associated PML.
Advances in nanotechnology for the diagnosis and management of autoimmune diseases
Published: April 30, 2026 10:00
Autoimmune diseases (AIDs) are chronic, heterogeneous disorders that are often diagnosed after irreversible tissue damage and treated with broad immunosuppression that fails to deliver durable remission. Nanotechnology offers opportunities to sense early…
Investigational approaches to multiple sclerosis therapy
Published: April 29, 2026 10:00
PURPOSE OF REVIEW: Multiple sclerosis (MS) research is entering a new therapeutic era. Beyond relapse rate reduction, the prevention of disability progression and, ideally, even the avoidance of disease development are now being formulated as new…
CAR T-Cell Therapy in Neurology: A Scoping Review of Neuro-Oncology, Autoimmune Diseases & Neurotoxicity
Published: April 28, 2026 10:00
Chimeric antigen receptor (CAR) T-cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers. This scoping…
Personalized medicine as a novel therapeutic approach for autoimmune diseases: new insights and future prospects
Published: April 28, 2026 10:00
Autoimmune diseases are caused by dysfunction of the immune system, leading to inappropriate attacks on healthy tissues. Because patients have diverse genetic predispositions and heterogeneous responses to therapy, personalized medicine (PM) offers an…
Impact of cladribine tablets on PROs in patients with MS: insights from the 1st interim analysis of the CLADFIT-MS study
Published: April 27, 2026 10:00
CONCLUSION: In this real-world cohort of patients with highly active MS, cladribine tablets treatment was associated with the maintenance of PROs over one year. The integration of wearable technology provided objective metrics that were consistent with…
Effects of thoracic manipulation with trigger point therapy on inflammatory cytokine levels in individuals with multiple sclerosis: a pilot study
Published: April 24, 2026 10:00
CONCLUSION: This study identified six cytokines/chemokines that had moderate to large effect sizes at multiple post-intervention timepoints favoring SM. Of these biomarkers, all are considered to be primarily pro-inflammatory. Such results support…